Limited evidenceGut health

Akkermansia Muciniphila

A genuinely interesting next-generation probiotic backed by strong mouse data and one small human proof-of-concept trial — but it has never been tested in a properly powered clinical trial, and the metabolic benefits being sold are extrapolated from 32 people over 3 months.

What the science says

Improves metabolic markers in overweight adults Limited evidence
The pivotal human study (Depommier, Nature Medicine 2019) randomised 32 overweight/obese insulin-resistant volunteers to placebo, live or pasteurised A. muciniphila for 3 months. Pasteurised bacteria improved insulin sensitivity (~+28%), reduced insulinaemia and total cholesterol, and produced a small weight difference (~-2.3 kg vs placebo); live bacteria did not significantly beat placebo. This was explicitly an exploratory safety and feasibility study, not an efficacy trial.
Low Akkermansia abundance is associated with obesity and metabolic disease Moderate evidence
Observational data consistently link lower faecal A. muciniphila to obesity, type 2 diabetes, inflammatory bowel disease and poorer response to cancer immunotherapy. These are associations — Akkermansia may be a marker of a healthy mucus layer rather than its cause, and supplementing has not been shown to reverse the associated disease.
Strengthens the intestinal mucus barrier Limited evidence
Mechanistic work identifies the outer-membrane protein Amuc_1100 as acting via TLR2 to improve gut barrier function, with convincing mouse data. Human barrier-function outcomes have not been demonstrated in a clinical trial.
Pasteurised cells outperform live cells Limited evidence
The counterintuitive finding that heat-killed cells beat live ones comes from a single underpowered trial and has not been replicated. Most commercial products use pasteurised cells on this basis, which is a reasonable but unconfirmed bet.

Dosage & safety

Studied doseThe human trial used 10^10 (10 billion) cells/day of pasteurised A. muciniphila MucT for 3 months. Commercial products typically supply 10^8-10^10 cells/day. Diet is a cheaper lever on the same target: polyphenol-rich foods (cranberry, grape, pomegranate) and fermentable fibres raise endogenous Akkermansia in human studies, and metformin does too.

SafetyThe 3-month trial reported no safety signal — liver and kidney markers, blood counts and adverse events were comparable to placebo. But human safety data amount to roughly two dozen exposed people over 12 weeks, so long-term safety is genuinely unknown. Theoretical concern: Akkermansia degrades intestinal mucin, and in mouse models of colitis and Salmonella infection mucin degradation has been detrimental — avoid in active IBD until human data exist. Avoid in immunocompromised individuals and pregnancy. It holds EU novel-food authorisation as pasteurised A. muciniphila and is sold under NDI notification in the US; products are expensive and viability or cell-count claims are hard to verify independently. Treat this as an early-stage supplement you are paying a premium to beta-test.

Scientific references

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Depommier C, Everard A, Druart C, et al. — Nat Med, 2019
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms
Cani PD, Depommier C, Derrien M, Everard A, de Vos WM — Nat Rev Gastroenterol Hepatol, 2022

Where to buy

Pendulum, Akkermansia 500 Pro , 30 Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Gut health

Probiotics Moderate evidence
Psyllium Husk (fiber) Strong evidence
L-Glutamine Limited evidence
Oregano Oil Limited evidence
Ginger Moderate evidence
Inulin (Prebiotic Fiber) Moderate evidence